Clinical Features

HIQA’s rapid assessment of RSV immunisation strategies

RSV is a highly contagious virus that infects the lungs and upper airways. It is transmitted by coughing, sneezing and breathing.

Respiratory syncytial virus (RSV) is a highly contagious virus that infects the lungs and upper airways. It is transmitted by coughing, sneezing and breathing.

Introduction: Respiratory syncytial virus (RSV) is a highly contagious virus that infects the lungs and upper airways. It is transmitted by coughing, sneezing and breathing. This virus spreads every winter, with the RSV season in Ireland typically running from October to March. In healthy individuals, infection with RSV is usually self-limiting; however, RSV can cause severe infections in some people, leading to hospitalisation. Groups vulnerable to serious complications include infants, young children and older adults.

In August 2024, the Health Information and Quality Authority (HIQA) published a rapid health technology assessment (HTA) to inform an interim Government policy decision on immunisation of infants and or older adults against RSV for the 2025-2026 season.

For verified healthcare professionals

Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.

Register for free Log in

Join the conversation

Comments are open to registered members. Log in or register to share your thoughts on this article.

Log in to comment Register for free